Seclidemstat (SP-2577)

Catalog No.S6722 Batch:S672201

Technical Data

Formula

C₂₀H₂₃ClN₄O₄S

Molecular Weight

450.94

CAS No.

1423715-37-0

Solubility (25°C)*

In vitro

DMSO

90 mg/mL (199.58 mM)

Water

˂1 mg/mL

Ethanol

˂1 mg/mL

In vivo (Add solvents to the product individually and in order)

Clear solution	5%DMSO 1 Corn oil	4.5mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 90 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution, mainly for i.p.	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	8.0mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 160 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 13 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.

Targets

LSD1/KDM1A ^[1]
(Cell-free assay)

13 nM

In vitro

The combination therapy of Seclidemstat (SP-2577) with checkpoint inhibitors may induce or augment immunogenic responses of SWI/SNF-mutated ovarian cancers. Seclidemstat promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) cell lines. Seclidemstat (3 μM) promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line.^[1]

In vivo

SP-2577 (Seclidemstat) is an inhibitor of lysine-specific demthylase KDM1A (LSD1) potential antineoplastic activity against pediatric sarcomas.

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) cell lines, ovarian clear cell carcinomas (OCCC) cell lines Concentrations 1μM,3 μM Incubation Time 72 h Method The SCCOHT and OCCC cell lines are seeded in T-25 tissue culture treated flasks at 3 x 10₅ cells in 5mL of the appropriate phenol red free complete growth medium. After 48 h, at 70–80% confluency, the cells are treated with 3μM or 1μM of Seclidemstat. After 72 h, the media is collected from the flasks and stored at -80°C until use for various assays.
Animal Study:^{^[3]}	Animal Models C.B.17SC scid−/− female mice Dosages 100 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) cell lines, ovarian clear cell carcinomas (OCCC) cell lines
Concentrations
1μM,3 μM
Incubation Time
72 h
Method
The SCCOHT and OCCC cell lines are seeded in T-25 tissue culture treated flasks at 3 x 10₅ cells in 5mL of the appropriate phenol red free complete growth medium. After 48 h, at 70–80% confluency, the cells are treated with 3μM or 1μM of Seclidemstat. After 72 h, the media is collected from the flasks and stored at -80°C until use for various assays.

Animal Study:^{^[3]}

Animal Models
C.B.17SC scid−/− female mice
Dosages
100 mg/kg
Administration
i.p.

References

Selleck's Seclidemstat (SP-2577) has been cited by 2 publications

Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma [ Nat Commun, 2024, 15(1):5631]	PubMed: 38965210
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51 [ Nat Commun, 2023, 10.1038/s41467-023-42850-x]	PubMed: 37973845

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.